- Conditions
- Healthy
- Interventions
- REG1
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Regulatory T-cells, Conventional T-cells, Melphalan, Thiotepa, Fludarabine, Anti-thymocyte globulin, rabbit, CliniMACS CD34 Reagent System
- Drug · Device
- Lead sponsor
- Everett Meyer
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Coronary Artery Disease
- Interventions
- pegnivacogin/anivamersen, Bivalirudin
- Drug
- Lead sponsor
- Regado Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Rapid City, South Dakota
- Conditions
- Acute Coronary Syndrome (ACS)
- Interventions
- REG1, Heparin
- Drug
- Lead sponsor
- Regado Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • Sacramento, California • San Diego, California + 21 more
- Conditions
- Coronary Artery Disease
- Interventions
- REG1, Unfractionated Heparin
- Drug
- Lead sponsor
- Regado Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Detroit, Michigan • Chapel Hill, North Carolina + 2 more
- Conditions
- Select Advanced Solid Tumors
- Interventions
- Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2041
- U.S. locations
- 1
- States / cities
- Houston, Texas